Literature DB >> 2547865

Amebic colitis masquerading as acute inflammatory bowel disease: the role of serology in its diagnosis.

A S Patel1, P H DeRidder.   

Abstract

Amebic colitis needs to be considered in the differential diagnosis of infectious colitis or inflammatory bowel disease (IBD). Misdiagnosing amebic colitis as idiopathic inflammatory disease may be fatal. Although stool studies remain the initial approach to diagnosis, the incidence of false-negatives associated with this method is high. We report two cases of amebic colitis presenting as inflammatory bowel disease in which the diagnosis of amebic colitis was made by serology. Neither patient had any risk factors for acquiring amebiasis. Paired serology for amebic infections (2-4 weeks apart) should be performed in patients being evaluated for infectious colitis and inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547865     DOI: 10.1097/00004836-198908000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Use of rapid dipstick and latex agglutination tests and enzyme-linked immunosorbent assay for serodiagnosis of amebic liver abscess, amebic Colitis, and Entamoeba histolytica Cyst Passage.

Authors:  H Rogier van Doorn; Henk Hofwegen; Rob Koelewijn; Henk Gilis; Ron Peek; Jose C F M Wetsteyn; Perry J J van Genderen; Tony Vervoort; Tom van Gool
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

2.  Colitis caused by Entamoeba histolytica identified by real-time-PCR and fluorescence in situ hybridization from formalin-fixed, paraffin-embedded tissue.

Authors:  Andreas Müller; Hagen Frickmann; Egbert Tannich; Sven Poppert; Ralf Matthias Hagen
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2022-09-22

Review 3.  Laboratory diagnosis of amebiasis.

Authors:  Mehmet Tanyuksel; William A Petri
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

4.  Invasive amoebiasis complicating iflammatory bowel disease.

Authors:  O Addib; H Ziglam; Pj Conlong
Journal:  Libyan J Med       Date:  2007-12-01       Impact factor: 1.657

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.